...
首页> 外文期刊>Journal of investigative medicine >Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease
【24h】

Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease

机译:成人镰状细胞病患者的慢性肾脏病患病率和进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aim: We evaluated the prevalence and progression of chronic kidney disease (CKD) during the 5-year period in a cohort of patients with sickle cell disease (SCD) aged 18 years and older. Methods: We studied 98 patients with SCD. Chronic kidney disease stages I through V were defined based on estimated glomerular filtration rate (eGFR), and albuminuria grades were defined based on spot urine protein-to-creatinine ratio according to the 2012 Kidney Disease Improving Global Outcomes recommendations. In patients with eGFR of greater than 60 mL/min per 1.73 m2, CKD was diagnosed if grade A2 or A3 albuminuria was present. Chronic kidney disease progression was defined as an increase in CKD stage with an additional eGFR reduction of more than 25% from baseline. Results: At baseline, 28.6% of patients had CKD. After a mean follow-up of 5.0 (SD, 0.9) years, 17 patients developed new CKD and the overall CKD prevalence increased to 41.8%. In addition, 8 patients experienced CKD progression. The following baseline variables were associated with the development and progression of CKD in univariate analysis: older age (P = 0.003), higher systolic blood pressure (BP; P = 0.003), lower eGFR (P = 0.001), higher serum creatinine (P = 0.001), and A3 albuminuria (P = 0.008). In multivariate analysis, baseline A3 albuminuria (adjusted odds ratio, 5.0; 95% confidence interval, 1.1-24.3; P = 0.048) and each 1-mm Hg increase in systolic BP (adjusted odds ratio, 1.04; 95% confidence interval, 1.0-1.07; P = 0.039) predicted CKD development and progression. Conclusions: Chronic kidney disease is common in patients with SCD and its prevalence increases with age. Several baseline modifiable and nonmodifiable factors were associated with the development and progression of CKD in patients with SCD. Strategies targeting BP control and proteinuria may be beneficial for individuals with SCD.
机译:目的:我们评估了一群18岁及以上镰状细胞疾病(SCD)患者在5年期间的慢性肾脏病(CKD)的患病率和进展。方法:我们研究了98例SCD患者。根据2012年肾脏病改善全球成果建议,根据估计的肾小球滤过率(eGFR)定义I至V期的慢性肾脏疾病,根据尿蛋白与肌酐的比值定义白蛋白尿分级。在每1.73平方米eGFR大于60 mL / min的患者中,如果存在A2或A3级蛋白尿,则应诊断为CKD。慢性肾脏疾病的进展定义为CKD期增加,eGFR较基线水平降低了25%以上。结果:基线时,有28.6%的患者患有CKD。在平均随访5.0(SD,0.9)年之后,有17例患者出现了新的CKD,并且CKD的总体患病率上升至41.8%。另外,有8名患者经历了CKD进展。在单变量分析中,以下基线变量与CKD的发生和发展相关:年龄较大(P = 0.003),收缩压较高(BP; P = 0.003),eGFR较低(P = 0.001),血清肌酐较高(P = 0.001)和A3蛋白尿(P = 0.008)。在多变量分析中,基线A3蛋白尿(校正比值比为5.0; 95%置信区间为1.1-24.3; P = 0.048)以及收缩压每升高1mm Hg(校正比值比为1.04; 95%置信区间为1.0) -1.07; P = 0.039)预测CKD的发生和发展。结论:慢性肾脏病在SCD患者中很常见,其患病率随年龄增长而增加。 SCD患者的一些基线可修改和不可修改因素与CKD的发生和发展有关。针对BP控制和蛋白尿的策略可能对SCD患者有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号